» Array BioPharma Advances P38 / Tie2 Inhibitor, ARRY-614, Into Phase 1 Clinical Trial
Array BioPharma Inc. (NASDAQ: ARRY) filed an Investigational New Drug (IND) application for ARRY-614 with the U.S. Food & Drug Administration and has initiated a Phase 1 clinical trial. ARRY-614, a…